Collegium Pharmaceutical (NASDAQ:COLL) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
Collegium Pharmaceutical (NASDAQ:COLL) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
Collegium Pharmaceutical (COLL): Revisiting Valuation After Fresh Coverage and Ongoing Earnings Outperformance [Yahoo! Finance]
Collegium Pharmaceutical (NASDAQ:COLL) had its "hold (c+)" rating reaffirmed by analysts at
Weiss Ratings.
Collegium Pharmaceutical (NASDAQ:COLL) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.